Noah M. Hahn

18.1k total citations · 7 hit papers
261 papers, 11.4k citations indexed

About

Noah M. Hahn is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Noah M. Hahn has authored 261 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Surgery, 112 papers in Oncology and 81 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Noah M. Hahn's work include Bladder and Urothelial Cancer Treatments (189 papers), Urinary and Genital Oncology Studies (106 papers) and Cancer Immunotherapy and Biomarkers (68 papers). Noah M. Hahn is often cited by papers focused on Bladder and Urothelial Cancer Treatments (189 papers), Urinary and Genital Oncology Studies (106 papers) and Cancer Immunotherapy and Biomarkers (68 papers). Noah M. Hahn collaborates with scholars based in United States, United Kingdom and Spain. Noah M. Hahn's co-authors include Nicholas J. Vogelzang, Christopher J. Sweeney, Matthew D. Galsky, Joel Picus, Joaquim Bellmunt, Peter H. O’Donnell, Mario A. Eisenberger, Michael A. Carducci, Guru Sonpavde and Glenn Liu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Noah M. Hahn

251 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

2015 1.8k citations Christopher J. Sweeney, Michael A. Carducci et al. profile →
Bladder cancer

2016 1.0k citations Noah M. Hahn, Seth P. Lerner et al. profile →
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

2017 939 citations Peter H. O’Donnell, Petros Grivas et al. profile →
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

2018 695 citations Michael A. Carducci, Noah M. Hahn et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Thomas Powles, Peter H. O’Donnell et al. profile →
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

2011 457 citations Matthew D. Galsky, Noah M. Hahn et al. Journal of Clinical Oncology profile →
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2019 435 citations Peter H. O’Donnell, Matthew D. Galsky et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noah M. Hahn United States	44	5.7k	4.5k	4.4k	2.2k	1.6k	261	11.4k
Guru Sonpavde United States	53	6.5k 1.1×	5.1k 1.1×	6.9k 1.5×	3.3k 1.5×	2.3k 1.4×	628	15.1k
Jonathan E. Rosenberg United States	51	7.0k 1.2×	4.1k 0.9×	5.5k 1.2×	4.2k 1.9×	2.1k 1.3×	404	13.5k
Matthew D. Galsky United States	55	6.5k 1.1×	3.8k 0.8×	5.6k 1.3×	3.3k 1.5×	1.6k 1.0×	393	13.2k
Matthew I. Milowsky United States	51	5.4k 1.0×	3.5k 0.8×	3.2k 0.7×	2.7k 1.2×	1.1k 0.7×	274	10.2k
Mitchell C. Benson United States	52	3.1k 0.5×	8.6k 1.9×	2.8k 0.6×	3.9k 1.8×	2.2k 1.3×	268	13.3k
Eric Winquist Canada	49	3.5k 0.6×	3.1k 0.7×	4.2k 1.0×	2.1k 1.0×	1.3k 0.8×	291	9.3k
Ulka N. Vaishampayan United States	56	2.8k 0.5×	7.3k 1.6×	5.7k 1.3×	5.0k 2.3×	3.1k 1.9×	495	12.8k
Ronald B. Natale United States	44	3.1k 0.5×	7.6k 1.7×	8.4k 1.9×	3.9k 1.8×	1.5k 0.9×	170	13.8k
Thomas W. Flaig United States	38	1.6k 0.3×	5.2k 1.1×	2.3k 0.5×	2.1k 0.9×	1.7k 1.0×	209	7.9k
Joan Carles Spain	39	2.5k 0.4×	3.1k 0.7×	2.4k 0.5×	1.2k 0.5×	1.0k 0.6×	327	6.2k

Countries citing papers authored by Noah M. Hahn

Since Specialization

Citations

This map shows the geographic impact of Noah M. Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah M. Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah M. Hahn more than expected).

Fields of papers citing papers by Noah M. Hahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah M. Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah M. Hahn. The network helps show where Noah M. Hahn may publish in the future.

Co-authorship network of co-authors of Noah M. Hahn

This figure shows the co-authorship network connecting the top 25 collaborators of Noah M. Hahn. A scholar is included among the top collaborators of Noah M. Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah M. Hahn. Noah M. Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vlachou, Evangelia, Burles A. Johnson, David J. McConkey, et al.. (2025). Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer. Cancer Research Communications. 5(9). 1674–1680.

Rezaee, Michael E., Bruce J. Trock, Armine K. Smith, et al.. (2024). ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol. BMJ Open. 14(6). e076763–e076763. 3 indexed citations

Vlachou, Evangelia, Burles A. Johnson, Roy Elias, et al.. (2024). Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.. Journal of Clinical Oncology. 42(4_suppl). 569–569. 1 indexed citations

Vlachou, Evangelia, et al.. (2024). Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts.. Journal of Clinical Oncology. 42(4_suppl). 544–544. 1 indexed citations

Inman, Brant A., Noah M. Hahn, Kelly Stratton, et al.. (2023). A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology. 6(3). 313–320. 21 indexed citations

Agrawal, Pranjal, Ridwan Alam, Katherine Rodríguez, et al.. (2023). Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder. Clinical Genitourinary Cancer. 21(6). 631–638.e1. 2 indexed citations

Parimi, Vamsi, Woonyoung Choi, Mingxiao Feng, et al.. (2023). Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder. Histopathology. 82(7). 991–1002. 3 indexed citations

Damrauer, Jeffrey S., Jeffrey A. Klomp, Mi Zhou, et al.. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13(1). 6658–6658. 27 indexed citations

Patel, Hiten D., Sunil Patel, Parth M. Patel, et al.. (2021). Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival. The Journal of Urology. 207(1). 77–85. 15 indexed citations

10.

Hoffman‐Censits, Jean, Woonyoung Choi, Trinity J. Bivalacqua, et al.. (2020). Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clinical Genitourinary Cancer. 19(2). 176–181. 11 indexed citations

11.

Ku, Geoffrey Y., A. W. Tolcher, Sara A. Hurvitz, et al.. (2020). 525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. Annals of Oncology. 31. S462–S463. 26 indexed citations

12.

Ooki, Akira, Maria Del Carmen Rodriguez Peña, Luigi Marchionni, et al.. (2017). YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. Cancer Research. 78(1). 168–181. 85 indexed citations

13.

Kates, Max, Thomas R. Nirschl, Nikolai A. Sopko, et al.. (2017). Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunology Research. 5(7). 594–603. 56 indexed citations

14.

Kates, Max, Abhijit A. Date, Takahiro Yoshida, et al.. (2017). Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 23(21). 6592–6601. 47 indexed citations

15.

Brant, Aaron, Max Kates, Meera R. Chappidi, et al.. (2016). Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. Urologic Oncology Seminars and Original Investigations. 35(1). 34.e17–34.e25. 16 indexed citations

16.

Ferrari, Alessio, G. R. Hudes, Michael A. Carducci, et al.. (2016). E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx). Annals of Oncology. 27. vi249–vi249. 1 indexed citations

17.

Michailidi, Christina, Masamichi Hayashi, Sayantan Datta, et al.. (2015). Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use. Cancer Prevention Research. 8(3). 208–221. 43 indexed citations

18.

Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533. 168 indexed citations

19.

Hahn, Noah M., Walter M. Stadler, Robin Zoň, et al.. (2011). Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology. 29(12). 1525–1530. 147 indexed citations

20.

Rossi, Carl J., I‐Chow Hsu, May Abdel–Wahab, et al.. (2011). ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer. American Journal of Clinical Oncology. 34(1). 92–98. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact